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Background: Since January 2008, the National Institutes of Health (NIH) has required that all investigators who
receive NIH support submit de-identified high-throughput genomic data to the database of Genotypes and
Phenotypes (dbGaP). The purpose of this study was to explore the feasibility of re-consenting participants from
three inactive studies, conducted from 2000 through 2009, to submit their data to dbGaP.
Methods: Participants were those enrolled in one of three prior population-based case-control studies of lung
cancer who had given a DNA sample. Consent to release de-identified data to dbGaP took place via mailed forms
and follow-up phone calls. Chi-squared tests were used to examine differences in re-contact and consent
proportions between groups.
Results: A total of 2,471 participants were initially eligible for re-contact. Six hundred and thirty-eight participants
were found to be deceased (n = 627) or did not give permission to re-contact (n = 11). Of the 1,833 remaining
participants, 42.3% provided written consent, 37.0% could not be located, 13.7% verbally agreed to have their data
released but never returned written consent, 5.3% refused, and 1.6% were too ill at the time of contact. There were
significant differences in ability to locate participants by age, race, gender, and case-control status; however, once
located, there were no differences in re-consent rates.
Conclusion: This study demonstrates that while most previous study participants agreed to release data, a small
proportion are opposed to submitting their data to dbGaP. In addition, it demonstrates the difficulty studies based
on existing samples may have in locating inactive participants for re-consent.Background
Starting in January 2008, the National Institutes of
Health (NIH) has required NIH-supported studies which
generate high-throughput genomic data to submit their
de-identified data to the database of Genotypes and
Phenotypes (dbGaP) [1,2]. Many current genome-wide
association studies (GWAS) include individuals who
have only consented to aims of the original study, mean-
ing that it may be necessary to re-contact participants* Correspondence: cotem@karmanos.org
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unless otherwise stated.to receive their consent for this additional use of their
data. The only published study to assess the outcomes
of re-consenting GWAS participants for this purpose is
from the Adult Changes in Thought (ACT) study, a lon-
gitudinal cohort study of ageing and dementia [3]. In
this study, of the 1,340 participants eligible for re-
consent, 1,159 (86%) agreed to submit their data to the
NIH central repository. A portion of the individuals
who consented were also asked their views about the re-
consenting process. The majority of respondents (69%)
reported that it was very important that their permis-
sion was asked. Many respondents considered alterna-
tives to consent, such as notification-only or opt-out, to
be unacceptable (67% and 40%, respectively) [3].d. This is an Open Access article distributed under the terms of the Creative
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tionships with participants during the time of their
re-consent, this current study examined the success of
re-consenting subjects who have had little or no contact
with research investigators for up to 10 years. The ori-
ginal aims of the three case-control studies included in
this analysis were to identify candidate genes or regions
associated with lung cancer. Similar to the ACT study, all
three studies drafted their original consent forms prior to
the NIH mandate that genomic research with NIH sup-
port be sent to the dbGaP. Here, we explored re-consent
feasibility and the willingness of study participants to sub-
mit their genomic data to dbGaP.
Methods
Subjects were enrolled in one of three prior Wayne State
University case-control studies: (1) the Family History
study (FHS), which focused on individuals aged less than
50 years at lung cancer diagnosis; (2) the Women’s Epi-
demiology of Lung Diseases (WELD) study, which enrolled
women with adenocarcinoma of the lung; and (3) the
Exploring Health, Ancestry, and Lung Epidemiology (EX-
HALE) study, a study of African Americans with lung
cancer [4]. These studies all received full board review and
approval from the Wayne State University Institutional
Review Board. All cases were identified through the
Metropolitan Detroit Cancer Surveillance System
(MDCSS), a part of the Surveillance, Epidemiology and
End Results (SEER) program. Controls in the metro-
politan Detroit area were identified through random
digit dialing (FHS and WELD) or were volunteers (EX-
HALE). All controls were frequency matched to cases
by 5-year age group, sex, and self-reported race. We
attempted to re-consent participants who had given a
blood sample in the original study to allow future GWAS
data to be submitted to an NIH central repository, dbGaP.
Eligible participants were those who were not known to
be deceased at the start of the re-consent process and
those who had indicated permission to be re-contacted on
their original consent form. The process of consenting eli-
gible participants started in February 2010. Data collected
before 24 March 2011 were included in this analysis.
Original study details
The FHS had DNA available for 141 cases and 250 con-
trols from 15 September 1990 to 30 September 2003.
Cases were defined as those aged less than 50 years
(mean age, 42.1 years) with a primary neoplasm of the
lung or bronchus. There were an equal number of men
and women, and 73.4% (n = 287) of the study population
self-identified as white and 22.0% (n = 86) as African
American, with 4.6% (n = 18) identifying as other races.
The WELD study recruited 530 cases and 529 controls
who provided a DNA sample. Cases were defined aswomen (age range, 18-74 years) diagnosed with primary
non-small cell lung cancer (NSCLC) between November
2001 and October 2005. The racial make-up of the sample
population was 76.7% (n = 812) white, 21.2% (n = 224) Af-
rican American, and 2.2% (n = 23) other races.
The EXHALE study recruited 464 African American
cases and 557 African American controls prior to revising
the consent form to allow for dbGaP submission at the
time of the initial consent. Cases diagnosed with lung can-
cer of any histology from 1 November 2005 to 31 October
2009 were eligible for the study. The study population was
47.0% men and 53.0% women.
Re-consenting process: mail
The names and social security numbers (when available)
of all subjects were linked to the MDCSS to identify de-
ceased individuals. Current addresses and telephone
numbers of participants who were not thought to be de-
ceased were obtained from MDCSS records, or through
Lexus Nexis, which provides a search engine to identify
past and current residential addresses and telephone
numbers based on applications to credit agencies. Those
eligible for re-contact (that is, not known to be deceased
and allowing future contact) were mailed an introduc-
tory letter reminding the subject of their previous study
participation and outlining the request for additional
consent to release their data to dbGaP. The packet also
contained two copies of the new consent form and a post-
age paid envelope, with the request to mail back the
signed consent form indicating whether they would agree
to release their data. The four-page consent form de-
scribed the study procedures as follows: ‘Allow us to sub-
mit both genetic and risk factor information (age, gender,
tobacco exposure, health status, etc.) to the NIH central
data repository. These data will not include your name,
address, phone number or any other usual identifiers.’
Re-consenting process: telephone follow-up
If the consent form was not returned after 1 month, an
interviewer followed up with a telephone call. The inter-
viewer tried the telephone number at various times dur-
ing morning, afternoon and evening hours during the
week and on Saturdays for 2 to 3 months. If the pro-
vided phone numbers were incorrect or disconnected,
alternate phone numbers were tried, if available. Consent
letters identified by the participant as lost, thrown away,
or never received were resent to a confirmed address.
Four interviewers conducted the participant phone calls
and were the same interviewers who had conducted most
of the participant interviews during the original studies.
An effort was made to match participants to their original
study interviewer. Upon reaching a participant on the
phone, the interviewers summarized the introductory
letter, asked the participant if they had received the
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plans to mail the letter back. Interviewers logged the
calls made to each participant. For the analyses of the
number of phone calls, letters sent to each participant
and detailed dialog with the participant, a randomized
sample of 105 call logs, 35 from each study, were used.
The participant’s re-consent results included: the date
the re-consent letter was sent, the date the re-consent
form was returned, the decision to participate (yes or no),
as well as the reasons a consent form was not returned
(invalid address, invalid phone number, both, and so on).
A limited amount of demographic information (age, race,
and sex) collected during the original studies was also
available for each subject. Chi-squared tests were used to
examine differences in re-contact and consent proportions
between groups, and a P value of <0.05 was considered




Figure 1 describes the outcome of the re-consenting
process. Of the 2,471 participants in the original studies,
no attempt was made to re-consent 638 individuals (n =
627 due to death and n = 11 because permission was not
granted to be re-contacted). Of the 1,833 where re-
contacted was attempted, 42.3% (n = 775) consented to
have their data submitted to dbGaP, 37.0% (n = 678)
could not be located, 13.7% (n = 252) told interviewers
that they planned to return the consent form in the fu-
ture but never did, 5.3% (n = 98) refused, and 1.6% (n =
30) were too sick to respond. Thus, a total of 1,402
(56.7%) of the original 2,471 study participants either
consented (n = 775) or were deceased (n = 627) and
could have their data submitted to dbGaP.
Our success at contacting living study subjects and
obtaining consent to submit data to dbGaP is shown in
Table 1. We attempted to contact 1,833 living former re-
search participants. The availability of correct contact infor-
mation varied significantly by study, gender, age, race, and
case or control status. Women, those aged more than
50 years at the time of the original study, whites, and cases
were significantly more likely to be contacted but these var-
iables were not associated with consent to submit data to
dbGaP (Table 1). Once contact was established, the study
(P value = 0.76), gender (P value = 0.05), age (P value =2,471--total 
subjects
638--no aempt to 
recontact













98--refused30--too ill to consider request
Figure 1 Outcome of re-contacting 2,471 case and control
participants from three population-based lung cancer studies.0.07), race (P value = 0.43), and case or control status (P
value = 0.48) did not impact whether a participant was will-
ing to consent to have their data submitted to dbGaP.
Overall, 11.3% (98/871) of the former research participants
who were located did not consent to release their data to
dbGaP.
Interviewer phone calls
Of the 105 phone call logs that were sampled, 370 phone
calls were made by the interviewers. An average of 3.5
phone calls were made to each participant and there
were 8.6 calls made per participant consent obtained.
The number of calls per consent differed with 12.6 calls
made per consent in the EXHALE study; 10.1 calls per
consent in the FHSIII study; and 5.5 calls made per con-
sent in the WELD study (data not shown).
Discussion
A total of 56.7% of the original 2,471 study participants ei-
ther consented or were deceased and therefore will have
their data submitted to dbGaP. Our local IRB allows for
submission of de-identified GWAS data from deceased in-
dividuals to be shared with dbGaP. Unfortunately, we
could not locate over one-third of our former study partic-
ipants. Of individuals contacted, 11.2% did not want their
data released. The number refusing data submission in
our study was similar to those in the Adult Changes in
Thought (ACT) study. This study reported that of their
1,311 participants who were re-consented, 88.4% (n =
1,159) agreed to submit their data to the NIH central re-
pository and 11.6% (n = 152) declined [3]. Unlike our
study where all re-consenting took place through the mail
or over the telephone, some (n = 353) of the re-consents
in the ACT study were obtained during bi-annual face-to-
face encounters between investigators and participants. Of
these 353 participants, 9.6% refused participation while
being consented in person [3]. This supports findings
from our study that suggest a consistent minority of par-
ticipants are opposed to submitting their data, regardless
of study methodologies or disease site.
While no other studies are known to have examined the
re-consent process, other studies have assessed the attitudes
of the public toward participation in genetic cohorts and
DNA data sharing. Focus groups with participants from a
genetic study of epilepsy noted that participants felt gen-
omic information should not be publically released without
explicit consent from research participants [5]. A survey of
the general U.S. adult population on their willingness to
participate in a large (hypothetical) genetic cohort study
in which participant DNA would be biobanked and made
available to a wider scientific community reported wide-
spread support (84%) but somewhat less agreement to
participate (60%) [6]. Some prior studies have suggested
that African Americans, women, older ages, lower income
Table 1 Living participants by re-contact status and consent
Contacteda (n = 1,820) Status of consentb (n = 871)
Yes No p-value Given Refused p-value
Study <0.0001 0.76
FHS 138 (48.6%) 146 (51.4%) 98 (90.7%) 10 (9.3%)
WELD 551 (73.3%) 201 (26.7%) 423 (88.7%) 54 (11.3%)
INHALE 456 (58.2%) 328 (41.8%) 252 (88.1%) 34 (11.9%)
Sex <0.0001 0.05
Male 238 (48.5%) 253 (51.5%) 122 (84.1%) 23 (15.9%)
Female 907 (68.3%) 422 (31.7%) 651 (89.7%) 75 (10.3%)
Age (years) <0.0001 0.07
<49 229 (51.0%) 220 (49.0%) 163 (92.6%) 13 (7.4%)
50+ 916 (66.8%) 455 (33.2%) 610 (87.8%) 85 (12.2%)
Race <0.0001 0.43
White 578 (72.2%) 223 (27.8%) 448 (89.8%) 51 (10.2%)
Black 550 (55.6%) 439 (44.4%) 312 (87.2%) 46 (12.9%)
Other 17 (56.7%) 13 (43.3%) 13 (92.9%) 1 (7.1%)
Status 0.0009 0.48
Case 362 (68.8%) 164 (31.2%) 248 (89.9%) 28 (10.1%)
Control 783 (60.5%) 511 (39.5%) 525 (88.2%) 70 (11.8%)
aExcludes 13 people for whom contact status was unclear/still pending.
bExcludes 274 people who were successfully contacted and verbally agreed but never sent back the form (n = 252), individuals who were contacted but too sick
to give informed consent (n = 30), and n = 2 individuals who were deceased but had next of kin return a consent form.
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likely to participate in genetic research or to allow their
samples to be banked for future study [7-9], although
these findings are not consistent [8]. Among individuals
who responded to our re-consent request, our study did
not find differences by age, race, gender, or case-control
status.
The detailed call logs kept by each interviewer gave us
the opportunity to qualitatively examine reasons given
for not returning the re-consent form. Common themes
included ‘forgetting to send back the form’ or mis-
placing/accidentally throwing the form away. One par-
ticipant conveyed fears of their data being ‘hacked into
through computer networks’ and others admitted that
they generally did not feel comfortable submitting their
data. These concerns are similar to those which have
been previously identified [6]. In addition, nearly half of
the call logs which contained dialog indicated that the
participant had forgotten that they had participated in the
original study. This is not uncommon, with a recent study
reporting that over one-quarter of individuals who were re-
cruited into genomic research studies did not recall signing
informed consent documents, and more than half could
not recall with whom they agreed to share their data [10].
Approaching research participants for additional per-
missions can be time-consuming and expensive [11]. We
estimate that the overall cost of our re-consent processwould be equal to the annual salary of one full-time
interviewer, which (including fringe benefits and indirect
costs) is roughly $47.60 per individual we attempted to
re-contact. This is comparable to the Ludman et al. study
which quoted $50 dollars per person, and employed a
similar protocol of following the initial letter with a tele-
phone call in the case of non-response [3]. In weighing
the cost versus the benefit of the re-consent process the
resources needed to replicate a study of this size must be
considered. It is likely the ability to re-use these data is a
much more economical approach when compared to
obtaining new study participants.
At this point there is no universal consensus as to how
participants in genomic research should be made aware
of the potential future uses or sharing of the data gener-
ated from their biospecimens. One suggestion is to use a
broad consent that allows continual research on collected
samples. Essentially, broad consent describes the future
deposition of genomic data into databases to allow sec-
ondary studies by other researchers, and may also include
the distribution of biospecimens for additional studies [2].
While broad consent may bypass the difficulty in re-
contacting participants to consent for secondary research,
debate remains about participant autonomy with this
approach [2,12]. In one study, the acceptability of broad
consent was almost evenly split; with 42% of individuals in
a biobank preferred to be asked permission for each
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form initially, while 48% would sign a broad consent form
for future research [6]. Others suggest that broad consent
and informed consent are not mutually exclusive, and
may indeed be the most preferable method for genomic
research [13]. Of course, broad consents constructed
today may not include the necessary language specific to
future projects and informed consent requirements, sug-
gesting research in this area will be ongoing. Continuous
engagement of research participants and the general pub-
lic regarding the risks and benefits of genomic research
has been recommended [14].
There are limitations to this analysis that should be con-
sidered. We could not locate over one-third of the partici-
pants from our lung cancer case-control studies. Due to the
dates of enrollment into the original studies, some of the
participants had not been contacted in 10 years. There is
little doubt that increased time between an initial study and
the re-consent process can present challenges in re-
contacting participants. Age at original interview, sex, and
race were all associated with the likelihood of obtaining a
participant’s current contact information. Younger partici-
pants may be more transient due to changes in marital sta-
tus and occupation. We also had more difficulty locating
African Americans and men. It is difficult to interpret why
these two demographics were more difficult to locate. In
addition, 13.7% of participants who were re-contacted
expressed that they planned to send in their re-consent
form when questioned on the phone, yet had not done so
after several months. While further telephone calls or
reminders might be helpful, it is also possible these indi-
viduals represent ‘soft’ refusals, and do not want their
information shared. Lastly, we were unable to draw con-
clusions about certain participant characteristics due to
wide variations in eligibility criteria between the three
studies. For example, it was difficult to determine the ef-
fects that time spent as an inactive participant had on
willingness to consent, versus race, age, or gender.
Conclusions
This study found a proportion of former study participants
are opposed to submitting their genetic and health data to
the NIH supported dbGaP database, which suggests these
re-consent efforts may be worthwhile and ethically neces-
sary when using data and specimens from past studies. It
also demonstrates the difficulties future studies may have in
locating inactive participants for re-consent, particularly in
mobile and minority populations.
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